Systemic and in vitro effects of GAD and GABA-T inhibitors on AADC activity and of AADC inhibitors on GAD.
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors*; D000311:Adrenal Glands / Q000201:enzymology; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001142:Aromatic-L-Amino-Acid Decarboxylases / Q000378:metabolism; D001545:Benserazide / Q000494:pharmacology; D001592:Benzyl Alcohols / Q000494:pharmacology; D002230:Carbidopa / Q000494:pharmacology; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003342:Corpus Striatum / Q000201:enzymology; D005260:Female; D005968:Glutamate Decarboxylase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006834:Hydrazines / Q000494:pharmacology; D010396:Penicillamine / Q000494:pharmacology; D051381:Rats; D000637:Transaminases / Q000037:antagonists & inhibitors*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001592:Benzyl Alcohols; D006834:Hydrazines; D001545:Benserazide; C004297:3-hydroxybenzylhydrazine; D000637:Transaminases; D000612:4-Aminobutyrate Transaminase; D002262:Carboxy-Lyases; D005968:Glutamate Decarboxylase; D001142:Aromatic-L-Amino-Acid Decarboxylases; D010396:Penicillamine; D002230:Carbidopa